NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

While those who've been here awhile know that I'm not a fan of the TTF Optune microwave helmet, the potential benefit of combining their treatment with DCVax-L is worth consideration.

Consider that 4 out of 8 is of course, 50%, and that those four were part of the 13% of 232 (300 patients that lived to 5 years (60 months). And those 4 patients were 13% of the total 30 that lived to at least 5 years.

One also should consider that if all eight of those who had used TTF had continued with their DCVax, would they have seen similar six year survival results as the four patients who did continue with both treatments? If so, that would have equaled 26% of the 30 patients using DCVax-L that lived to at least 5 years.

It would be nice for investors to know the methylation status of all 8 of these TTF patients.

From Jama:

"Eight of the 232 patients (3.4%) receiving DCVax-L were treated with tumor-treating fields (TTF) following recurrence. Four of those 8 patients (50.0%) continued receiving DCVax-L while using the TTF device after recurrence and survived from 22.6 to more than 72.7 months from randomization. Four of the 8 patients (50.0%) stopped receiving DCVax-L while using the TTF device post-recurrence, and survived from 8.9 to 29.2 months from randomization."
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847